Frankfurt
18.09.25 | 08:07
0,075 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09. | Alzinova AB: Alzinova Receives FDA (IND) Approval for Phase II Study of ALZ-101 in Alzheimer's Disease | 81 | GlobeNewswire (Europe) | Alzinova AB (publ) (Nasdaq First North: ALZ) today announces that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for its planned Phase... ► Artikel lesen | |
| 28.08. | Alzinova - Innovative new approach to Alzheimer's | 289 | Edison Investment Research | Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments for Alzheimer's disease (AD) via protein modification and immunotherapy-based solutions. Alzinova's... ► Artikel lesen | |
| 21.08. | Alzinova AB Q2 Sales Increase | - | RTTNews | ||
| ALZINOVA Aktie jetzt für 0€ handeln | |||||
| 21.08. | Alzinova AB: Alzinova publishes half-year January - June 2025 | 107 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the half-year report for the period January - June 2025. The full report, which is attached in the press release... ► Artikel lesen | |
| 11.08. | Alzinova AB: Alzinova submits applications for clinical trial initiation (IND) and Fast Track status to the FDA | 248 | GlobeNewswire (Europe) | Alzinova AB (publ) (Nasdaq First North: ALZ) today announced that the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for the planned... ► Artikel lesen | |
| 19.06. | Alzinova AB: Alzinova's ALZ-101 vaccine shows new promising results in normalizing protective antibody levels in Alzheimer's disease patients | 177 | GlobeNewswire (Europe) | Alzinova AB (ALZ) announces new clinical results showing that healthy elderly people naturally have high levels of protective antibodies against toxic amyloid-ß oligomers, which are reduced in Alzheimer's... ► Artikel lesen | |
| 17.06. | Alzinova AB: Alzinova selects Worldwide Clinical Trials as CRO partner for Phase 2 study of ALZ-101 | 418 | GlobeNewswire (Europe) | Alzinova AB (Nasdaq First North: ALZ) today announces a strategic collaboration with Worldwide Clinical Trials ("Worldwide"), a global leader in neuroscience studies, appointing them as the Clinical... ► Artikel lesen | |
| 28.05. | Alzinova AB: Bulletin from the Annual General Meeting of Alzinova AB (publ) | 179 | GlobeNewswire (Europe) | Alzinova AB (publ) (the "Company") held its Annual General Meeting ("AGM") in Gothenburg on 28 May 2025. The following resolutions were passed at the meeting.
Adoption of the annual accounts and discharge... ► Artikel lesen | |
| 15.05. | Alzinova AB: Alzinova publishes interim report January - March 2025 | 148 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2025. The full report, which is attached in the press release,... ► Artikel lesen | |
| 24.04. | Alzinova AB: Alzinova Advances ALZ-101 Development with Drug Substance Release, Paving the Way for Phase 2 Clinical Trial | 230 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This... ► Artikel lesen | |
| 11.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 11.04.2025 | 448 | Xetra Newsboard | Das Instrument J1X BMG4660A1036 HIMALAYA SHIPPING LTD DL1 EQUITY wird cum Kapitalmassnahme gehandelt am 11.04.2025 und ex Kapitalmassnahme am 14.04.2025 The instrument J1X BMG4660A1036 HIMALAYA SHIPPING... ► Artikel lesen | |
| 02.04. | Alzinova AB: The Board of Directors of Alzinova resolves on a rights issue of shares of approximately SEK 35.7 million | 180 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, CANADA, THE UNITED... ► Artikel lesen | |
| 27.03. | Alzinova AB: Final results confirm positive phase 1b results with ALZ-101 against Alzheimer's disease | 428 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's disease... ► Artikel lesen | |
| 07.03. | Alzinova AB: Bulletin from the Extraordinary General Meeting of Alzinova AB (publ) | 185 | GlobeNewswire (Europe) | The following resolution were passed at the extraordinary general meeting (the "EGM") of Alzinova AB (publ) ("the Company") on 7 March 2025 in Gothenburg.
Long-term incentive program (LTIP 2025:1 for... ► Artikel lesen | |
| 27.02. | Alzinova AB: Alzinova publishes year-end report 2024 | 249 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report for the period January - December, and the fourth quarter, 2024. The full report, which is attached... ► Artikel lesen | |
| 03.02. | Alzinova AB: All study participants have completed the final visit in the Phase 1 study | 259 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) announces that another milestone in the development of the company's vaccine candidate ALZ-101 for Alzheimer's disease has been reached. All study participants have... ► Artikel lesen | |
| 28.01. | Alzinova AB: Alzinova strategically realigns CMO position to enhance collaboration and drive next development phase | 373 | GlobeNewswire (Europe) | Alzinova AB (publ) (ticker: ALZ) hereby announces that the Company's CMO is stepping down from her role after mutual agreement. The basis is a strategic decision to appoint a CMO in place at the Company's... ► Artikel lesen | |
| 09.12.24 | Alzinova AB: Alzinova reports positive results from the phase 1b extension part of the ALZ-101 study in Alzheimer's disease | 317 | GlobeNewswire (Europe) | ALZ-101 continues to demonstrate a favorable safety and tolerability profile after at least 84 weeks of study inclusion.The immune response from vaccination with ALZ-101 is robust and long-lasting in... ► Artikel lesen | |
| 14.11.24 | Alzinova AB: Alzinova publishes interim report January - September 2024 | 266 | GlobeNewswire (Europe) | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September, and the third quarter, 2024. The full interim report, which... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,905 | +1,16 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
| 89BIO | 14,970 | +85,27 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
| BIONTECH | 81,80 | -1,51 % | Community-Rückblick: BNTX Rally nur von kurzer Dauer: "Die Top-Meldung ist zu nem Non-Event geworden" | BioNTech konnte einen Durchbruch nach der Phase-3-Studie zum Brustkrebspräparat "Trastuzumab Pamirtecan" vermelden. Diese Nachricht trieb die Aktie zweistellig nach oben. Die Rally war allerdings nur... ► Artikel lesen | |
| EVOTEC | 6,292 | +1,26 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,120 | 0,00 % | Fortschritte in der Pipeline: H.C. Wainwright bestätigt "Buy"-Rating für Beam Therapeutics | ||
| SUMMIT THERAPEUTICS | 19,280 | 0,00 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| RAPPORT THERAPEUTICS | 27,350 | +3,91 % | Truist Securities initiates Rapport Therapeutics stock with Buy rating | ||
| NURIX THERAPEUTICS | 8,970 | 0,00 % | Nurix reports promising preclinical data for IRAK4 degrader GS-6791 | ||
| MINERALYS THERAPEUTICS | 39,880 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,925 | 0,00 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
| DAY ONE BIOPHARMACEUTICALS | 7,210 | +3,07 % | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,140 | +13,35 % | AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play? | ||
| PRIME MEDICINE | 5,120 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,890 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 41,850 | +4,47 % | Roth/MKM initiates Avidity Biosciences stock with Buy rating on platform potential |
Das Unternehmen ALZINOVA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,075 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZINOVA AB finden Sie auf Wallstreet Online.